Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
---|---|---|---|---|---|
Novartis | 1541 | 958 | 100.0% | 306 | major |
GlaxoSmithKline | 1191 | 717 | 100.0% | 359 | major |
Pfizer | 897 | 562 | 99.8% | 216 | major |
Merck Sharp & Dohme (MSD) | 859 | 506 | 99.8% | 187 | major |
Roche | 800 | 410 | 99.0% | 167 | major |
Sanofi S.A. | 751 | 390 | 99.7% | 264 | major |
Astrazeneca | 743 | 410 | 97.3% | 108 | major |
Johnson & Johnson | 579 | 324 | 99.7% | 122 | major |
Eli Lilly | 490 | 314 | 99.4% | 71 | major |
Medical University of Vienna | 439 | 263 | 92.8% | 34 | major |
Bristol-Myers Squibb | 408 | 213 | 100.0% | 88 | major |
Boehringer Ingelheim | 400 | 309 | 100.0% | 44 | major |
Hospitals of Paris (AP-HP) | 344 | 59 | 23.7% | 46 | major |
Bayer | 343 | 244 | 100.0% | 55 | major |
Amgen Inc | 308 | 193 | 100.0% | 54 | major |
Novo Nordisk | 279 | 180 | 100.0% | 39 | major |
Radboud University Medical Centre | 270 | 92 | 85.9% | 53 | major |
KU Leuven | 265 | 155 | 97.4% | 13 | major |
Gilead Sciences Inc | 264 | 171 | 100.0% | 55 | major |
Rigshospitalet | 262 | 141 | 51.8% | 25 | major |
Abbvie | 260 | 128 | 99.2% | 53 | major |
Takeda | 253 | 150 | 100.0% | 57 | major |
No Sponsor Name Given | 244 | 84 | 67.9% | 23 | major |
Erasmus University | 241 | 14 | 78.6% | 30 | major |
UCB | 234 | 124 | 100.0% | 84 | major |
University of Amsterdam | 231 | 25 | 40.0% | 31 | major |
Aarhus University | 221 | 115 | 64.3% | 14 | major |
Charité-Universitätsmedizin Berlin | 210 | 161 | 96.3% | 6 | major |
Agostino Gemelli University Polyclinic | 193 | 13 | 15.4% | 111 | major |
VU University Medical Centre | 187 | 30 | 40.0% | 18 | major |
University of Groningen | 183 | 11 | 72.7% | 11 | major |
Leiden University | 181 | 12 | 58.3% | 17 | major |
Merck KGaA | 179 | 121 | 99.2% | 30 | major |
Utrecht University | 172 | 27 | 51.9% | 45 | major |
University College London | 163 | 90 | 98.9% | 6 | major |
IRCCS Ospedale San Raffaele | 160 | 54 | 100.0% | 12 | major |
Astellas | 157 | 109 | 100.0% | 29 | major |
Ghent University | 155 | 66 | 54.5% | 42 | major |
Servier Laboratories | 152 | 116 | 100.0% | 20 | major |
Celgene | 149 | 71 | 100.0% | 28 | major |
Allergan | 148 | 103 | 97.1% | 25 | major |
University of Oxford | 146 | 86 | 100.0% | 0 | major |
Imperial College London | 145 | 103 | 100.0% | 1 | major |
Karolinska University Hospital | 140 | 25 | 40.0% | 13 | major |
Biogen | 137 | 86 | 96.5% | 24 | major |
Medical University of Graz | 136 | 75 | 80.0% | 9 | major |
IRCCS Azienda Ospedaliero-Universitaria di Bologna | 135 | 4 | 100.0% | 34 | major |
Novartis Vaccines | 132 | 65 | 100.0% | 63 | major |
Helsinki University | 130 | 36 | 33.3% | 9 | major |
Eisai Inc. | 128 | 69 | 100.0% | 41 | major |
Pierre Fabre S.A. | 122 | 98 | 99.0% | 7 | major |
Odense University Hospital | 118 | 70 | 92.9% | 16 | major |
University of Birmingham | 118 | 53 | 100.0% | 5 | major |
Chiesi Farmaceutici S.p.A | 115 | 76 | 100.0% | 19 | major |
Shire | 115 | 70 | 100.0% | 31 | major |
Oslo University Hospital | 115 | 17 | 52.9% | 9 | major |
Vertex Pharmaceuticals, Inc. | 113 | 57 | 100.0% | 36 | major |
European Organisation for the Research and Treatment of Cancer (EORTC) | 110 | 63 | 100.0% | 15 | major |
Abbott | 109 | 87 | 96.6% | 18 | major |
Hospices Civils de Lyon | 108 | 23 | 26.1% | 10 | major |
King’s College London | 107 | 73 | 98.6% | 4 | major |
Herlev and Gentofte Hospital | 106 | 59 | 66.1% | 10 | major |
Université libre de Bruxelles | 106 | 23 | 69.6% | 10 | major |
National Cancer Institute Italy (Istituto Nazionale dei Tumori) | 105 | 4 | 50.0% | 23 | major |
Actelion Pharmaceuticals Ltd | 99 | 65 | 100.0% | 20 | major |
Teva | 98 | 76 | 98.7% | 14 | major |
Ipsen | 95 | 63 | 100.0% | 18 | major |
H. Lundbeck A/S | 94 | 70 | 98.6% | 11 | major |
Regeneron Pharmaceuticals Inc. | 92 | 30 | 100.0% | 31 | major |
Antoni van Leeuwenhoek Hospital | 88 | 5 | 80.0% | 8 | major |
CSL Behring | 86 | 52 | 100.0% | 27 | major |
Daiichi Sankyo | 86 | 48 | 100.0% | 17 | major |
Karolinska Institutet | 86 | 31 | 87.1% | 13 | major |
Incyte Corporation | 86 | 24 | 95.8% | 14 | major |
Unicancer | 85 | 14 | 85.7% | 3 | major |
Alexion Pharmaceuticals, Inc | 84 | 35 | 97.1% | 19 | major |
Fundació Clínic per a la Recerca Biomèdica | 83 | 6 | 33.3% | 28 | major |
Guy's and St Thomas' NHS Foundation Trust | 82 | 50 | 94.0% | 2 | major |
University of Munich (Ludwig-Maximilians) | 82 | 47 | 78.7% | 6 | major |
University of Cologne | 82 | 45 | 95.6% | 1 | major |
Maastricht University | 82 | 13 | 53.8% | 12 | major |
Genentech | 81 | 58 | 100.0% | 8 | major |
Otsuka | 81 | 55 | 100.0% | 15 | major |
Innsbruck Medical University | 80 | 52 | 94.2% | 5 | major |
CHU de Toulouse | 77 | 15 | 6.7% | 13 | major |
Alcon | 76 | 44 | 100.0% | 31 | major |
University of Dundee | 74 | 69 | 100.0% | 1 | major |
University of Leeds | 72 | 52 | 98.1% | 0 | major |
Menarini Group | 71 | 56 | 100.0% | 6 | major |
NHS Greater Glasgow and Clyde | 71 | 40 | 100.0% | 2 | major |
LEO Pharma A/S | 70 | 52 | 100.0% | 9 | major |
Vrije Universiteit Brussel | 70 | 8 | 62.5% | 6 | major |
European Institute of Oncology | 70 | 1 | 0.0% | 17 | major |
The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 56 | 92.9% | 1 | major |
Galderma R&D | 69 | 52 | 100.0% | 4 | major |
Bispebjerg Hospital | 69 | 43 | 51.2% | 7 | major |
University Hospital Tübingen | 69 | 37 | 89.2% | 4 | major |
Vall d'Hebron University Hospital | 69 | 22 | 86.4% | 15 | major |
Technical University of Munich | 68 | 46 | 97.8% | 12 | major |
Heidelberg University Hospital | 68 | 37 | 91.9% | 3 | major |
Cliniques Universitaires Saint-Luc | 67 | 17 | 88.2% | 13 | major |
ACCORD (University of Edinburgh & NHS Lothian) | 66 | 44 | 93.2% | 2 | major |
Queen Mary University of London | 65 | 42 | 100.0% | 4 | major |
Baxter | 64 | 49 | 95.9% | 8 | major |
University of Turku | 64 | 18 | 50.0% | 2 | major |
Hospital de la Santa Creu i Sant Pau | 64 | 12 | 66.7% | 12 | major |
University of Nottingham | 63 | 57 | 100.0% | 1 | major |
Manchester University NHS Foundation Trust | 63 | 53 | 100.0% | 0 | major |
Mario Negri Institute | 63 | 31 | 100.0% | 13 | major |
CHU Clermont-Ferrand | 63 | 12 | 0.0% | 7 | major |
Almirall S.A. | 62 | 51 | 100.0% | 6 | major |
University Erlangen-Nuremberg | 62 | 30 | 86.7% | 5 | major |
Gothenburg University | 61 | 12 | 50.0% | 8 | major |
Ferring Pharmaceuticals | 60 | 52 | 100.0% | 5 | major |
The Royal Marsden NHS Foundation Trust | 60 | 29 | 82.8% | 2 | major |
CHU de Bordeaux | 60 | 12 | 16.7% | 11 | major |
Hvidovre Hospital | 58 | 32 | 46.9% | 7 | major |
Policlinico San Matteo | 58 | 4 | 0.0% | 38 | major |
HOVON Foundation | 58 | 3 | 100.0% | 4 | major |
Hannover Medical School | 57 | 45 | 28.9% | 6 | major |
University Hospitals of Leicester NHS Trust | 56 | 45 | 97.8% | 5 | major |
Belfast Health and Social Care Trust | 55 | 45 | 97.8% | 1 | major |
Mundipharma | 55 | 45 | 93.3% | 4 | major |
University of Hamburg | 55 | 26 | 100.0% | 0 | major |
AOU Policlinico di Modena | 55 | 6 | 16.7% | 24 | major |
Octapharma AG | 54 | 32 | 100.0% | 14 | major |
The Lymphoma Study Association (LYSA) | 54 | 21 | 85.7% | 3 | major |
Skåne University Hospital | 54 | 13 | 46.2% | 10 | major |
Johannes Gutenberg University of Mainz | 53 | 35 | 68.6% | 5 | major |
BioMarin Pharmaceutical Inc | 53 | 23 | 78.3% | 10 | major |
King's College Hospital NHS Foundation Trust | 52 | 41 | 95.1% | 2 | major |
University of Freiburg | 52 | 26 | 88.5% | 3 | major |
Barts Health NHS Trust | 51 | 44 | 97.7% | 4 | major |
University Hospital Southampton NHS Foundation Trust | 51 | 20 | 65.0% | 2 | major |
Cambridge University Hospitals NHS Foundation Trust | 50 | 41 | 95.1% | 1 | major |
RWTH Aachen University | 50 | 29 | 89.7% | 13 | major |
University of Antwerp | 50 | 7 | 42.9% | 8 | major |